With the $250 service, Color is hoping to broaden access to genetic testing and make it easier for researchers to incorporate genetics in their studies.
Launching a diverse product pipeline will also test Helix's ability to manage the challenges of providing genomics interpretations to a broad consumer audience.
The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.
The new company believes it can be the dominant clearinghouse for genome analysis apps or other tools, with free and unlimited storage of users' genomic data.
As many as 10,000 Nevadans will get free genetic testing through a large population health study being conducted by non-profit care network Renown Health.
Early backers can get their genome or exome sequenced at discounted rates of $999 and $399, respectively, limited to the first 10 and 50 users in each case.
The company has developed a panel of 15 genes, identified from scientific literature, that specifically link to an athlete's potential to respond to power or endurance training.
Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
